Successful long-term management of choroidal neovascularization secondary to angioid streaks in a patient with pseudoxanthoma elasticum: a case report

Journal of Medical Case Reports

Aldo Caporossi¹  Benedetto Falsini¹  Gaetano Zinzanella¹  Angelo Maria Minnella¹  Maria Cristina Savastano¹ 

[1] Ophthalmology, Catholic University “Sacro Cuore – A. Gemelli”, Largo “A. Gemelli” 8, 00168 Rome, Italy

关键词: Ranibizumab;    Pseudoxanthoma elasticum;    Choroidal neovascularization;    Bevacizumab;    Angioid streaks;   

Others  :  1180862
DOI  :  10.1186/1752-1947-8-458

 received in 2014-09-17, accepted in 2014-11-13,  发布年份 2014

【 摘 要 】

Introduction

We describe the long-term effectiveness and tolerability of intravitreal vascular endothelial growth factor inhibitor ranibizumab in a patient with pseudoxanthoma elasticum with bilateral macular choroidal neovascularization secondary to angioid streaks.

Case presentation

A 54-year-old Caucasian man with history of heart disease presented with visual loss in his right eye. An examination revealed choroidal neovascularization and reduced visual acuity, while no abnormalities were seen in his left eye. He was diagnosed with angioid streaks associated with pseudoxanthoma elasticum. Off-label treatment with intravitreal bevacizumab once a month initiated in December 2007 was discontinued after 3 months due to lack of efficacy. In September 2008, the patient reported reduced visual acuity in his left eye and an examination revealed changes. Left eye treatment was initiated in October 2008 with a loading dose (three consecutive monthly intravitreal injections of ranibizumab 0.5mg/50μL) followed by 0.5mg/50μL followed by treatment as needed until May 2014. After 21 ranibizumab injections, an examination revealed angioid streaks and choroidal neovascularization in both eyes. His right eye showed retinal layer deterioration with outer limiting membrane and photoreceptor inner/outer segment junction involvement. His left eye had a smaller foveal scar, with other areas preserved. Visual acuity was stable in his treated left eye, but had deteriorated in his right eye. Ranibizumab treatment was well tolerated with no adverse events reported.

Conclusions

In the present case, an as-needed regimen of ranibizumab after an initial loading dose, achieved maintenance of visual function and was well tolerated over a period of almost 6 years in a patient with pseudoxanthoma elasticum and high cardiovascular risk. As anti-vascular endothelial growth factor agents are associated with increased risk of systemic effects, particularly arterial thromboembolic events, following intravenous administration, the absence of serious thromboembolic or cardiovascular adverse events throughout the 6-year treatment period is particularly encouraging considering our patient’s high cardiovascular risk status.

【 授权许可】

   
2014 Savastano et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Finger RP, Charbel Issa P, Ladewig MS, Gotting C, Szliska C, Scholl HP, Holz FG: Pseudoxanthoma elasticum: genetics, clinical manifestations and therapeutic approaches. Surv Ophthalmol 2009, 54:272-285.
• [2]Georgalas I, Papaconstantinou D, Koutsandrea C, Kalantzis G, Karagiannis D, Georgopoulos G, Ladas I: Angioid streaks, clinical course, complications, and current therapeutic management. Ther Clin Risk Manag 2009, 5:81-89.
• [3]Gupta B, Elagouz M, Sivaprasad S: Intravitreal bevacizumab for choroidal neovascularisation secondary to causes other than age-related macular degeneration. Eye (Lond) 2010, 24:203-213.
• [4]Lucentis 10mg/mL solution for injection: Summary of Product Characteristics [http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000715/WC500043546.pdf webcite]
• [5]Finger RP, Charbel Issa P, Hendig D, Scholl HP, Holz FG: Monthly ranibizumab for choroidal neovascularizations secondary to angioid streaks in pseudoxanthoma elasticum: a one-year prospective study. Am J Ophthalmol 2011, 152:695-703.
• [6]Finger RP, Charbel Issa P, Schmitz-Valckenberg S, Holz FG, Scholl HN: Long-term effectiveness of intravitreal bevacizumab for choroidal neovascularization secondary to angioid streaks in pseudoxanthoma elasticum. Retina 2011, 31:1268-1278.
• [7]Mimoun G, Tilleul J, Leys A, Coscas G, Soubrane G, Souied EH: Intravitreal ranibizumab for choroidal neovascularization in angioid streaks. Am J Ophthalmol 2010, 150:692-700. e691
• [8]Shah M, Amoaku WM: Intravitreal ranibizumab for the treatment of choroidal neovascularisation secondary to angioid streaks. Eye (Lond) 2012, 26:1194-1198.
• [9]Jung JJ, Freund KB: Long-term follow-up of outer retinal tubulation documented by eye-tracked and en face spectral-domain optical coherence tomography. Arch Ophthalmol 2012, 130:1618-1619.
• [10]Zebardast N, Adelman RA: Intravitreal ranibizumab for treatment of choroidal neovascularization secondary to angioid streaks in pseudoxanthoma elasticum: five-year follow-up. Semin Ophthalmol 2012, 27:61-64.
• [11]Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ: Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011, 364:1897-1908.
• [12]Ventrice P, Leporini C, Aloe JF, Greco E, Leuzzi G, Marrazzo G, Scorcia GB, Bruzzichesi D, Nicola V, Scorcia V: Anti-vascular endothelial growth factor drugs safety and efficacy in ophthalmic diseases. J Pharmacol Pharmacother 2013, 4:S38-S42.
• [13]Xu L, Lu T, Tuomi L, Jumbe N, Lu J, Eppler S, Kuebler P, Damico-Beyer LA, Joshi A: Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: a population approach. Invest Ophthalmol Vis Sci 2013, 54:1616-1624.
• [14]Zehetner C, Kirchmair R, Huber S, Kralinger MT, Kieselbach GF: Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema. Br J Ophthalmol 2013, 97:454-459.
• [15]Wolff B, Matet A, Vasseur V, Sahel JA, Mauget-Faysse M: En face OCT imaging for the diagnosis of outer retinal tubulations in age-related macular degeneration. J Ophthalmol 2012, 2012:542417.